Sandbox/diarrhea: Difference between revisions
No edit summary |
No edit summary |
||
Line 219: | Line 219: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
Line 229: | Line 229: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Moxifloxacin]] 400 mg orally q6h AND [[Clindamycin]] 300 mg orally q6h'''''<BR> OR <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 1 double-strength tablet orally q12h AND [[metronidazole]] 250 to 500 mg orally q6h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Moxifloxacin]] 400 mg orally q6h AND [[Clindamycin]] 300 mg orally q6h'''''<BR> OR <BR> ▸ '''''[[Trimethoprim-sulfamethoxazole]] 1 double-strength tablet orally q12h AND [[metronidazole]] 250 to 500 mg orally q6h''''' | ||
|- | |- | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
Line 249: | Line 249: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompetent patients}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
Line 255: | Line 255: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] (> 12weeks) 45 mg/kg/day orally in 2 divided doses for 5 days ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin-clavulanate]] (> 12weeks) 45 mg/kg/day orally in 2 divided doses for 5 days ''''' | ||
|- | |- | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF| | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Immunocompromised patients}} | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' |
Revision as of 13:43, 27 May 2014
WikiDoc Resources for Sandbox/diarrhea |
Articles |
---|
Most recent articles on Sandbox/diarrhea Most cited articles on Sandbox/diarrhea |
Media |
Powerpoint slides on Sandbox/diarrhea |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Sandbox/diarrhea at Clinical Trials.gov Trial results on Sandbox/diarrhea Clinical Trials on Sandbox/diarrhea at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Sandbox/diarrhea NICE Guidance on Sandbox/diarrhea
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Sandbox/diarrhea Discussion groups on Sandbox/diarrhea Patient Handouts on Sandbox/diarrhea Directions to Hospitals Treating Sandbox/diarrhea Risk calculators and risk factors for Sandbox/diarrhea
|
Healthcare Provider Resources |
Causes & Risk Factors for Sandbox/diarrhea |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mugilan Poongkunran M.B.B.S [2]
Antibiotic Therapy
Pathogen Specific
▸ Click on the following categories to expand treatment regimens.[1][2]
Shigella species ▸ Adults ▸ Children Non-typhi species of Salmonella ▸ Adults ▸ Children Campylobacter species ▸ Adults ▸ Children Escherichia coli species ▸ Enterotoxigenic ▸ Enteropathogenic ▸ Enteroinvasive ▸ Enteroaggregative ▸ Enterohemorrhagic (STEC) Aeromonas / Plesiomonas ▸ Adults ▸ Children Yersinia species ▸ Adults ▸ Children Vibrio cholerae O1 or O139 ▸ Adults ▸ Children Toxigenic Clostridium difficile ▸ Adults ▸ Children Parasites ▸ Giardia ▸ Cryptosporidium species ▸ Isospora species ▸ Cyclospora species ▸ Microsporidium species ▸ Entamoeba histolytica |
|
References
- ↑ Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.
- ↑ Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC; et al. (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)". Infect Control Hosp Epidemiol. 31 (5): 431–55. doi:10.1086/651706. PMID 20307191.